Mylan bags rights to distribute Gilead's Sovaldi in India

Gilead ($GILD) has named Mylan ($MYL) as the exclusive distributor of branded forms of its hepatitis C blockbusters Sovaldi and Harvoni in India. The deal comes 5 months after Gilead gave Mylan and other manufacturers nonexclusive rights to produce and distribute generic versions of the drugs. Those agreements are still in place. The new deal adds another piece to Gilead's hepatitis C strategy in India by paving the way for sales of its branded products. Mylan expects to begin distribution in the second quarter of 2015. Release | More from The Wall Street Journal (sub. req.)

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.